ABT vs MDT Stock Comparison: AI Score, Valuation, Performance and Upside
Abbott and Medtronic are both large-cap diversified medical device companies with long dividend histories, but Abbott has executed significantly better in recent years. Abbott's FreeStyle Libre CGM has been one of healthcare's biggest product launch successes. Medtronic is a turnaround story. Both are dividend aristocrats; Abbott's growth trajectory is significantly stronger.
ABT vs MDT is a medtech portfolio with FreeStyle Libre CGM driving above-market execution (Abbott) versus the world's largest medical device company in recovery mode pursuing Hugo robotic surgery and organic growth improvement (Medtronic) — Abbott's current execution advantage versus Medtronic's scale and recovery potential.
MDT holds the edge across 3 of 5 key metrics in this comparison. MDT leads on both 1-year return (-3.62%) and forward P/E quality (14.24x vs 16.81x for ABT), a relatively favorable combination of momentum and valuation. On fundamentals, ABT is growing revenue faster (13.00%), while MDT maintains the higher operating margin (22.05%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for ABT (+17.96%) than for MDT (+8.34%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- prefer a medtech compounder with FreeStyle Libre CGM as a subscription-like high-growth market share leader in diabetes management
- value Abbott's diversification across devices, diagnostics, nutrition, and pharmaceuticals across multiple healthcare segments
- want medtech dividend income with 50+ consecutive dividend increase years alongside above-market organic device growth
- are comfortable with COVID diagnostics revenue normalization and Dexcom competition in the CGM market
- prefer the world's largest medical device company with 40+ year dividend growth history as a reliable medtech income investment
- value Medtronic's global distribution scale across 150+ countries providing consistent healthcare market access in developing and developed markets
- want recovery upside if Hugo robotic surgery and Ardian renal denervation establish meaningful commercial traction against Intuitive's dominance
- are comfortable with organic growth consistently lagging peers and extended timeline to competitive Hugo adoption
| Metric | ABT | MDT |
|---|---|---|
| AI scorei | 50.3 | 41.2 |
| AI ranki | #528 | #1072 |
| Latest closei | $102.61 | $92.13 |
| 1M returni | -10.33% | -2.12% |
| 6M returni | -4.27% | +6.06% |
| 1Y returni | -23.75% | -3.62% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABT | MDT |
|---|---|---|
| 1Y ago | $7.63K (-23.7%) started 2025-09-18 | $9.64K (-3.6%) started 2025-09-18 |
| 5Y ago | $9.47K (-5.3%) started 2021-09-20 | $9.09K (-9.1%) started 2021-09-20 |
| 10Y ago | $34.41K (+244.1%) started 2016-09-19 | $17.08K (+70.8%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | ABT | MDT |
|---|---|---|
| Market capi | $176.41B | $116.77B |
| Trailing P/Ei | 32.99 | 24.46 |
| Forward P/Ei | 16.81 | 14.24 |
| Price/Salesi | 5.49 | N/A |
| EV/Revenuei | 4.38 | 3.78 |
| Analyst targeti | $120.26 | $98.84 |
| Target upsidei | +17.96% | +8.34% |
| Metric | ABT | MDT |
|---|---|---|
| Revenue growthi | 13.00% | 9.90% |
| Earnings growthi | -47.50% | 18.30% |
| EPS growthi | -47.50% | +18.30% |
| FCF margini | +15.48% | +12.72% |
| Operating margini | 14.71% | 22.05% |
| Profit margini | 11.65% | 13.20% |
| ROIC proxyi | 10.58% | 9.84% |
| Return on equityi | 10.58% | 9.84% |
| Dividend yieldi | 2.47% | 3.16% |
| Payout ratioi | 78.96% | 70.20% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.59 | 0.57 |
| Debt/equityi | 63.21 | 58.21 |
| Current ratioi | 1.38 | 2.13 |
| Quick ratioi | 0.80 | 1.36 |
Over the past year, ABT and MDT have moved moderately in the same direction (correlation of 0.54), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ABT | MDT |
|---|---|---|---|
| 1Y | Growthi | -23.75% | -3.62% |
| CAGRi | -23.76% | -3.62% | |
| Volatilityi | 26.76% | 23.51% | |
| Sharpe ratioi | -1.05 | -0.23 | |
| Sortino ratioi | -1.45 | -0.35 | |
| Max drawdowni | 39.57% | 30.00% | |
| Current drawdowni | 24.89% | 12.55% | |
| Avg drawdowni | 19.30% | 12.68% | |
| Ulcer Indexi | 22.21% | 15.35% | |
| Max daily dropi | 10.04% | 5.11% | |
| Max wkly dropi | 13.11% | 7.05% | |
| 5Y | Growthi | -11.88% | -19.60% |
| CAGRi | -2.50% | -4.27% | |
| Volatilityi | 23.04% | 22.49% | |
| Sharpe ratioi | -0.19 | -0.28 | |
| Sortino ratioi | -0.27 | -0.38 | |
| Max drawdowni | 40.85% | 43.47% | |
| Current drawdowni | 26.48% | 21.16% | |
| Avg drawdowni | 17.55% | 26.61% | |
| Ulcer Indexi | 19.81% | 27.79% | |
| Max daily dropi | 10.04% | 7.26% | |
| Max wkly dropi | 13.11% | 11.81% | |
| 10Y | Growthi | +189.17% | +33.62% |
| CAGRi | +11.21% | +2.94% | |
| Volatilityi | 24.01% | 23.55% | |
| Sharpe ratioi | 0.38 | 0.05 | |
| Sortino ratioi | 0.54 | 0.07 | |
| Max drawdowni | 40.85% | 45.10% | |
| Current drawdowni | 26.48% | 23.43% | |
| Avg drawdowni | 10.84% | 17.80% | |
| Ulcer Indexi | 14.55% | 22.08% | |
| Max daily dropi | 10.04% | 12.82% | |
| Max wkly dropi | 16.72% | 19.36% |
| Category | ABT | MDT |
|---|---|---|
| Company | Abbott Laboratories | Medtronic plc |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | Abbott is a diversified medical device and diagnostics company with four segments: Medical Devices (cardiovascular, structural heart, neuromodulation), Diagnostics (rapid tests, core lab), Established Pharmaceuticals (branded generics in emerging markets), and Nutrition (Ensure, Similac). Abbott's FreeStyle Libre continuous glucose monitoring (CGM) system is its fastest-growing product — a subscription-like model with 6M+ active users. | Medtronic is the world's largest pure-play medical device company by revenue, covering cardiovascular, neuroscience, medical-surgical, and diabetes management across 150+ countries. Its Hugo robotic surgery system and Ardian renal denervation system are key growth bets as Medtronic pursues organic revenue recovery after years of underperforming the medtech market. |
| Investor focus | Investors track FreeStyle Libre CGM revenue growth, cardiac rhythm management recovery, structural heart device growth, and Diagnostics core lab stabilization after COVID testing normalization. | Investors track organic revenue growth recovery (the primary metric vs peers), Hugo surgical robot commercial progress, Ardian renal denervation market development, and dividend sustainability. |
- FreeStyle Libre CGM dominates the continuous glucose monitoring market with 6M+ users and subscription-like sensor repurchase economics
- Portfolio diversification across devices, diagnostics, nutrition, and pharmaceuticals provides multiple growth vectors
- Dividend Aristocrat with 50+ consecutive years of dividend increases — among the most reliable medtech income investments
- World's largest medical device company with $32B+ in revenue and established global distribution in 150+ countries
- Dividend paid and increased for 40+ consecutive years — a very reliable medtech income investment with long aristocrat history
- Strong installed base in cardiac rhythm management providing upgrade cycle revenue across its global hospital customer base
- FreeStyle Libre faces competition from Dexcom's G7/G8 sensors and potential disruption from closed-loop insulin delivery integration
- Post-COVID diagnostics normalization created meaningful revenue headwinds as COVID testing demand collapsed
- Established pharmaceuticals in emerging markets adds currency risk from geographic exposure to developing economies
- Organic revenue growth has consistently lagged Boston Scientific, Abbott, Stryker, and other medtech peers for several years
- Hugo robot competes against Intuitive Surgical's da Vinci with thousands of installations and decades of surgeon training
- Diabetes business faces competition from Abbott's FreeStyle Libre and Dexcom in CGM, pressuring Medtronic's insulin delivery strategy
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.